Evenity (Romosozumab) Mental Health and Mood Impact

What the FDA Label Says About Romosozumab and Mood

The FDA prescribing information for Evenity does not list depression, anxiety, mania, or any other psychiatric disorder under adverse reactions, warnings, or precautions. The Boxed Warning focuses exclusively on major adverse cardiovascular events. In the pooled safety database submitted for approval, psychiatric events were not reported at a frequency that triggered a labeling requirement.

That absence is clinically meaningful but not conclusive. Phase 3 trials are powered for fracture endpoints, not psychiatric outcomes, and spontaneous mood changes in a population already managing a serious bone disease are difficult to attribute to a single agent.

What the Boxed Warning Actually Covers

The Boxed Warning added to Evenity in April 2019 warns that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. FDA drug approval package documents show this signal emerged from ARCH, where the romosozumab arm had a 2.5% cardiovascular event rate versus 1.9% in the alendronate arm over the first 12 months. No analogous signal appeared for neuropsychiatric events.

Adverse Events Reported in the Key Trials

Adverse events reported at 2% or higher in ARCH included arthralgia, headache, injection-site reactions, and nasopharyngitis. ARCH (Saag et al., NEJM 2017) enrolled 4,093 postmenopausal women and showed romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months (P<0.001). Headache was listed; mood change was not flagged as an event exceeding the threshold for tabulation.

The Biology: Does Sclerostin Affect the Brain?

This is where the science gets genuinely interesting. Sclerostin, encoded by the SOST gene, was long considered a bone-specific secreted glycoprotein. More recent work shows it is expressed in neurons, particularly in the hippocampus and cortex.

Wnt Signaling and Mood Regulation

Wnt/beta-catenin signaling is not exclusive to bone. A 2018 review in Neuropsychopharmacology documented that Wnt pathway disruption in rodent hippocampal circuits produces depressive-like behavior, and lithium's mood-stabilizing effects are partly attributed to GSK-3beta inhibition, a downstream Wnt effector. Blocking sclerostin theoretically amplifies Wnt signaling in any tissue that expresses the pathway, including neural tissue.

Preclinical Data on Sclerostin and Cognition

A 2020 study published in Bone found that SOST-knockout mice showed altered hippocampal morphology and changes in spatial memory tasks compared to wild-type controls. The direction of effect in those animals was toward improved, not impaired, cognition. One rodent model cannot predict human psychiatric outcomes, but the data do suggest sclerostin plays a role in CNS Wnt tone that deserves prospective study.

Why Systemic Blockade May Not Reach the Brain

Romosozumab is a large IgG2 monoclonal antibody with a molecular weight of approximately 150 kDa. Antibodies of this size cross the intact blood-brain barrier at roughly 0.1% of plasma concentrations under normal physiologic conditions, according to pharmacokinetic modeling discussed in CNS Drugs (2022). At the 210 mg monthly dose, peak serum concentrations reach approximately 22.2 mcg/mL by week 1, meaning CNS exposure is likely in the range of 0.02 mcg/mL. Whether that is sufficient to alter sclerostin-mediated Wnt tone in human hippocampal tissue remains unknown.

FRAME and ARCH: What the Phase 3 Trials Measured

The two key trials for romosozumab were FRAME (N=7,180) and ARCH (N=4,093). Neither trial used a validated psychiatric rating scale as a pre-specified endpoint.

FRAME Trial Overview

FRAME (Cosman et al., NEJM 2016) randomized postmenopausal women with osteoporosis to romosozumab 210 mg monthly or placebo for 12 months, then all participants transitioned to denosumab 60 mg every 6 months for another 12 months. At 12 months, romosozumab reduced new vertebral fractures by 73% versus placebo (P<0.001). The safety data from FRAME documented injection-site reactions, arthralgia, and headache as the most common adverse events. No mood or psychiatric category appeared in the safety tables.

ARCH Trial Overview

ARCH (Saag et al., NEJM 2017) was an active-controlled trial comparing romosozumab followed by alendronate versus alendronate alone in 4,093 postmenopausal women. Over 24 months, the combination sequence cut new vertebral fractures by 48% (P<0.001) and nonvertebral fractures by 19% (P=0.04). The safety population was large enough that even a modest psychiatric signal would likely have surfaced in spontaneous reporting if it existed at a clinically meaningful frequency.

Limitations of Trial-Based Psychiatric Surveillance

Phase 3 trials rely on spontaneous adverse-event reporting unless psychiatric endpoints are pre-specified. Patients with active severe depression or psychosis were excluded from both ARCH and FRAME per standard trial protocols. CONSORT guidelines note that exclusion criteria narrow safety populations in ways that can mask signals in subgroups. Women with subclinical mood disorders or on antidepressants at baseline would likely have been included, but their mood status was not tracked with validated instruments such as the PHQ-9 or HAM-D.

Osteoporosis, Chronic Disease, and Mood: Separating Drug from Disease

Severe osteoporosis is itself associated with reduced quality of life and elevated rates of depression. A meta-analysis in Osteoporosis International (2019) found that individuals with osteoporosis had a 65% higher odds of depression compared with age-matched controls without the condition (OR 1.65, 95% CI 1.42-1.92). This baseline elevation creates a confounding problem: any mood change observed during romosozumab treatment may reflect the natural course of osteoporosis-related psychological burden rather than a drug effect.

Fear of Fracture and Its Psychological Toll

Fear of falling and fracturing is a well-documented psychological construct in older adults with osteoporosis. A 2021 systematic review in Age and Ageing documented that fear of falling independently predicted depressive symptoms, activity restriction, and reduced social participation, all independent of actual fall frequency. A patient beginning romosozumab after a fragility fracture is entering treatment from a psychologically compromised starting point.

Does Fracture Reduction Improve Mood?

There is a plausible positive pathway: if romosozumab prevents fractures, and fractures drive depression, then effective treatment may modestly improve mood over the 12-month course. No romosozumab trial has tested this hypothesis directly. Data from bisphosphonate trials offer a partial comparison. A secondary analysis of the FIT trial (N=2,027) found no significant difference in self-reported well-being between alendronate and placebo at 36 months, suggesting fracture reduction alone may not translate to measurable mood improvement in trial settings.

Cardiovascular Risk, Beta-Blockers, and Indirect Mood Effects

The Evenity Boxed Warning for cardiovascular risk has a secondary psychiatric implication. Patients who experience a myocardial infarction or stroke during treatment may develop subsequent major depressive disorder. Post-MI depression occurs in approximately 20% of patients, according to a review in Circulation (2008). Prescribers who initiate romosozumab in patients with prior cardiovascular events (the labeled contraindication) could theoretically increase this downstream psychiatric risk through the cardiovascular pathway. This is not a direct drug-mood effect, but it is a clinically relevant indirect chain.

Who Should Not Receive Romosozumab

The FDA label contraindicates Evenity in patients who have had an MI or stroke within the preceding year. Endocrine Society Clinical Practice Guidelines for osteoporosis (2019) align with this restriction and recommend romosozumab only when the benefit-to-risk ratio clearly favors treatment, typically in patients with T-score at or below -2.5 and at least one prior fragility fracture or very high FRAX probability.

Post-Marketing Reports: Any Psychiatric Signal?

The FDA Adverse Event Reporting System (FAERS) is a voluntary database and is subject to reporting bias, but it can generate hypothesis-forming signals. As of publicly available FAERS quarterly data through Q1 2025, psychiatric adverse events for romosozumab have not appeared in FDA MedWatch public summaries or drug safety communications as a flagged safety concern. The FDA MedWatch page for Evenity does not list a psychiatric safety update.

Spontaneous reports from patients on social media and forums do include anecdotal accounts of mood changes, fatigue, and irritability, but these are not systematically collected or causally attributable. The rate of such reports is not higher than would be expected for any injectable chronic-disease medication in an older female population.

Clinical Monitoring Framework for Prescribers

Given the biological plausibility of CNS Wnt involvement and the absence of controlled psychiatric data, a structured but proportionate monitoring approach is reasonable during the 12-month romosozumab course.

Baseline Assessment Before Starting Evenity

Screen all patients with the PHQ-9 before the first injection. Document a score. Patients with a PHQ-9 of 10 or higher should have their depression addressed before or concurrently with romosozumab initiation, not because Evenity is contraindicated in depression but because untreated depression independently worsens osteoporosis outcomes through reduced physical activity and medication adherence. A 2020 analysis in JBMR Plus found that depressed patients had 34% lower bisphosphonate adherence at 12 months compared to non-depressed patients.

Month 3 and End-of-Treatment Check-In

A brief PHQ-2 screen at month 3 and again at month 12 (the end of the romosozumab course) adds approximately 90 seconds to a follow-up visit and creates a documented record. If PHQ-2 is positive (score 2 or higher), follow with the full PHQ-9. This is not a standard of care requirement but is consistent with the American Association of Clinical Endocrinology (AACE) emphasis on comprehensive patient management in osteoporosis, outlined in their 2020 Clinical Practice Guidelines.

When to Involve Psychiatry

No evidence currently supports stopping romosozumab for mood symptoms alone. If a patient develops new moderate-to-severe depression (PHQ-9 above 14) during treatment, refer to psychiatry or initiate appropriate pharmacotherapy based on standard guidelines, continue the romosozumab course unless another cause for discontinuation exists, and document the temporal relationship for potential FAERS reporting. Adding to the post-marketing database strengthens the signal-detection capacity for future patients.

What Patients Actually Ask About Mood and Evenity

Patients who research Evenity online frequently find forum posts describing fatigue, low energy, and emotional flatness in the days after the monthly injection. These symptoms overlap with the known injection-site reaction profile and with the normal fatigue response to any new injectable biologic. A pharmacovigilance study of biologics for inflammatory arthritis (BMJ Open, 2021) noted that injection fatigue and transient mood dip in the 24-72 hours after subcutaneous biologics are common class effects, likely driven by mild cytokine response rather than the drug's primary mechanism.

Romosozumab does not have a significant immunogenicity-driven cytokine release profile comparable to TNF-alpha inhibitors or IL-6 blockers, but low-level injection-site immune activation can still produce transient systemic symptoms. These typically resolve within 48 hours and do not require treatment modification.

Comparison With Other Osteoporosis Agents and Psychiatric Profiles

No major osteoporosis drug has a psychiatric adverse effect listed as a primary labeling concern, but individual agents have relevant nuances worth noting.

Teriparatide (Forteo) and abaloparatide (Tymlos), both anabolic PTH/PTHrP analogs, share no known psychiatric signal. Denosumab (Prolia) labeling does not list psychiatric events. Bisphosphonates as a class have been associated in some observational studies with lower rates of depression, possibly because fracture prevention itself is mood-protective; a cohort study in Calcified Tissue International (2017) found a 14% lower incidence of new depression diagnoses in bisphosphonate users over 5 years (HR 0.86, 95% CI 0.79-0.93).

Romosozumab's 12-month time-limited course distinguishes it from long-term agents. Any transient mood perturbation, if it exists, would be self-limiting once the drug is discontinued and the patient transitions to antiresorptive therapy.

Practical Prescribing Takeaways

Romosozumab remains a high-priority option for postmenopausal women with T-score at or below -2.5 and prior vertebral fracture, as supported by ARCH and FRAME and endorsed by the Endocrine Society 2019 guidelines. The cardiovascular Boxed Warning, not any psychiatric concern, is the primary safety constraint on its use.

Clinicians should document baseline mood with a validated tool, watch for cardiovascular events that could secondarily drive depression, and report any apparent psychiatric adverse events to FAERS to build the post-marketing evidence base.

The biologically interesting question of whether blocking sclerostin modifies human mood through CNS Wnt pathways deserves a prospective study. Until that trial exists, the working clinical conclusion is: no confirmed psychiatric signal, plausible mechanistic pathway, and a monitoring approach that takes 90 seconds per visit.